4/23
12:34 pm
pcvx
Mammalian Cell Fermentation Technology Market anticipated journey towards the lucrative US$ 68 Billion valuation. At a CAGR of 10% by 2034 | Future Market Insights, Inc. [Yahoo! Finance]
Low
Report
Mammalian Cell Fermentation Technology Market anticipated journey towards the lucrative US$ 68 Billion valuation. At a CAGR of 10% by 2034 | Future Market Insights, Inc. [Yahoo! Finance]
4/10
08:05 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $95.00 price target on the stock.
Medium
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $95.00 price target on the stock.
4/7
08:01 am
pcvx
Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst [Seeking Alpha]
Low
Report
Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst [Seeking Alpha]
4/2
04:05 pm
pcvx
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
3/27
10:16 am
pcvx
Ford Hutman Media Announces the Promotion of Julia Fuller to Managing Partner [Yahoo! Finance]
Neutral
Report
Ford Hutman Media Announces the Promotion of Julia Fuller to Managing Partner [Yahoo! Finance]
3/26
02:10 am
pcvx
Sutro Biopharma GAAP EPS of -$1.78 beats by $1.31, revenue of $153.73M beats by $101.4M [Seeking Alpha]
Low
Report
Sutro Biopharma GAAP EPS of -$1.78 beats by $1.31, revenue of $153.73M beats by $101.4M [Seeking Alpha]
3/25
04:43 pm
pcvx
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones [Yahoo! Finance]
Low
Report
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones [Yahoo! Finance]
3/4
08:42 am
pcvx
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants [Yahoo! Finance]
Low
Report
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants [Yahoo! Finance]
3/4
08:30 am
pcvx
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
Low
Report
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
2/28
01:30 pm
pcvx
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know [Yahoo! Finance]
Low
Report
Vaxcyte, Inc. (PCVX) Is Up 2.14% in One Week: What You Should Know [Yahoo! Finance]
2/28
10:12 am
pcvx
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Vaxcyte, Inc. (NASDAQ:PCVX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/28
08:17 am
pcvx
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Needham & Company LLC from $73.00 to $95.00. They now have a "buy" rating on the stock.
Medium
Report
Vaxcyte, Inc. (NASDAQ: PCVX) had its price target raised by analysts at Needham & Company LLC from $73.00 to $95.00. They now have a "buy" rating on the stock.
2/27
04:10 pm
pcvx
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
2/27
04:01 pm
pcvx
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Medium
Report
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/26
09:57 am
pcvx
Why Vaxcyte (PCVX) Might Surprise This Earnings Season [Yahoo! Finance]
Low
Report
Why Vaxcyte (PCVX) Might Surprise This Earnings Season [Yahoo! Finance]
2/22
11:33 pm
pcvx
Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares [Yahoo! Finance]
Medium
Report
Insider Sell: Vaxcyte Inc CFO Andrew Guggenhime Disposes of 8,000 Shares [Yahoo! Finance]
2/15
04:14 pm
pcvx
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 [Yahoo! Finance]
Low
Report
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 [Yahoo! Finance]
2/15
04:05 pm
pcvx
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Low
Report
Vaxcyte to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
2/2
11:23 pm
pcvx
Director Heath Lukatch Sells 5,000 Shares of Vaxcyte Inc (PCVX) [Yahoo! Finance]
Low
Report
Director Heath Lukatch Sells 5,000 Shares of Vaxcyte Inc (PCVX) [Yahoo! Finance]
2/2
06:39 pm
pcvx
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Vaxcyte Announces Closing of $862.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/1
11:18 pm
pcvx
Director Heath Lukatch Sells 4,000 Shares of Vaxcyte Inc (PCVX) [Yahoo! Finance]
Low
Report
Director Heath Lukatch Sells 4,000 Shares of Vaxcyte Inc (PCVX) [Yahoo! Finance]
2/1
04:20 pm
pcvx
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference [Yahoo! Finance]
Low
Report
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference [Yahoo! Finance]
2/1
04:05 pm
pcvx
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
Low
Report
Vaxcyte to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
1/30
11:37 pm
pcvx
Vaxcyte Announces Pricing of $750 Million Public Offering
Medium
Report
Vaxcyte Announces Pricing of $750 Million Public Offering
1/30
04:28 pm
pcvx
Vaxcyte announces commencement of proposed public offering [Seeking Alpha]
Medium
Report
Vaxcyte announces commencement of proposed public offering [Seeking Alpha]